To understand the epidemiology of multidrug-resistant (MDR) *Acinetobacter baumannii* and define individual risk factors for multidrug resistance, we used epidemiologic methods, performed organism typing by pulsed-field gel electrophoresis (PFGE), and conducted a matched case-control retrospective study. We investigated 118 patients, on 27 wards in Israel, in whom MDR *A. baumannii* was isolated from clinical cultures. Each case-patient had a control without MDR *A. baumannii* and was matched for hospital length of stay, ward, and calendar time. The epidemiologic investigation found small clusters of up to 6 patients each with no common identified source. Ten different PFGE clones were found, of which 2 dominated. The PFGE pattern differed within temporospatial clusters, and antimicrobial drug susceptibility patterns varied within and between clones. Multivariate analysis identified the following significant risk factors: male sex, cardiovascular disease, having undergone mechanical ventilation, and having been treated with antimicrobial drugs (particularly metronidazole). Penicillins were protective. The complex epidemiology may explain why the emergence of MDR *A. baumannii* is difficult to control.

*Acinetobacter baumannii* has emerged as an important nosocomial pathogen (1–5). Hospital outbreaks have been described from various geographic areas (6–9), and this organism has become endemic in some of them. The role of the environmental contamination in the transmission of nosocomial infections in general and in *A. baumannii* infections in particular is well recognized (10,11). *A. baumannii* does not have fastidious growth requirements and is able to grow at various temperatures and pH conditions (12). The versatile organism exploits a variety of both carbon and energy sources. These properties explain the ability of *Acinetobacter* species to persist in either moist or dry conditions in the hospital environment, thereby contributing to transmission (13,14). This hardiness, combined with its intrinsic resistance to many antimicrobial agents, contributes to the organism’s fitness and enables it to spread in the hospital setting.

The nosocomial epidemiology of this organism is complex. Villegas and Hartstein reviewed *Acinetobacter* outbreaks occurring from 1977 to 2000 and hypothesized that endemicity, increasing rate, and increasing or new resistance to antimicrobial drugs in a collection of isolates suggest transmission. These authors suggested that transmission should be confirmed by using a discriminatory genotyping test (15). The importance of genotyping tests is illustrated by outbreaks that were shown by classic epidemiologic methods and were thought to be caused by a single isolate transmitted between patients; however, when molecular typing of the organisms was performed, a more complex situation of multiple unrelated strains causing the increasing rates of infections by *A. baumannii* was discovered (16–18).

Almost 25 years ago, researchers observed acquired resistance of *A. baumannii* to antimicrobial drugs commonly used at that time, among them aminopenicillins, ureidopenicillins, first and second-generation cephalosporins, cephemycins, most aminoglycosides, chloramphenicol, and tetracyclines (19). Since then, strains of *A. baumannii* have also gained resistance to newly developed antimicrobial drugs. Although multidrug-resistant (MDR) *A. baumannii* is rarely found in community isolates, it became prevalent in many hospitals (20). MDR *A. baumannii* has recently been established as a leading nosocomial pathogen in several Israeli hospitals, including our institution (21,22). Several locally contained small outbreaks of MDR *A. baumannii* occurred in our institution during the late 1990s. In 1999, however, the incidence of MDR *A. baumannii* isolation had doubled compared to the previous 2 years, and the organism became endemic in many wards (unpub. data).

The likelihood of isolation of *A. baumannii* from a hospitalized patient is related to temporospatial (extrinsic, ecologic characteristics) factors such as colonization...
pressure (23), nurse-to-patient ratio, and other ward characteristics and to individual patient risk factors (characteristics). The current study was designed to examine the occurrence and spread of *A. baumannii* within our institution, as well as to define individual risk factors for isolation of this organism.

**Methods**

**Hospital Setting, Data Collection, and Microbiologic Testing**

This study was performed at the Tel-Aviv Sourasky Medical Center, Israel, a 1,200-bed tertiary care teaching hospital with 70,000 admissions annually. Approximately 82,500 clinical microbiologic cultures are processed annually. We designed this as a matched case-control study to identify the individual risk factors for having MDR *A. baumannii*. We also performed epidemiologic investigations and genetic typing of the organisms to clarify the spread of this nosocomial pathogen.

Case-patients were defined as patients from whom MDR *A. baumannii* was isolated from any clinical culture (not surveillance cultures) during a 6-month period, from January 1, 2001, to June 30, 2001. A control patient was matched to each study patient on temporospatial factors as previously described (24). Briefly, controls were randomly chosen from the list of patients who stayed on the same ward in the same calendar month as the matched case-patient and who were hospitalized for at least the same number of days by the day the culture yielded MDR *A. baumannii* in the study patient. Controls were not MDR *A. baumannii* positive (i.e., the patient’s samples were cultured, and either non-MDR *A. baumannii* or no *A. baumannii* was isolated, or the patient’s samples were never cultured). Random control selection was performed by creating a list of all possible controls, assigning each candidate a random number, and choosing the highest random number (without replacement).

Case-patients and control patients were included only once in the study. Data were collected from the patients’ records and from hospital computerized databases into a pre-prepared electronic questionnaire (Microsoft Access, Microsoft Corp., Redmond, WA, USA). The parameters registered for each patient (case-patients and controls) were age, sex, habits of smoking and alcohol consumption before hospitalization, cause and ward of hospitalization, transfer from another institution or ward within our institution, intensive care unit (ICU) stay, underlying disorders, immunosuppressive therapy, severity of illness as defined by the McCabe score (25), functional capacity and neurologic condition at time of isolation of *A. baumannii*, Foley catheter, invasive devices, surgery, mechanical ventilation, dialysis, infection, and antimicrobial drug therapy. Only variables occurring before inclusion in the study (culture day for case-patients and match day for controls) were analyzed as possible risk factors. *A. baumannii* was isolated from clinical specimens submitted to the microbiology laboratory and identified by using the Gram-Negative Identification Panel (Microscan, Dade Behring Inc., Sacramento, CA, USA). This system may not distinguish between closely related genotypic strains of *Acinetobacter*, and thus, some of these organisms may belong to these closely related strains. Susceptibilities were determined by automated microdilution broth testing (Neg/Urine Combo panel, Dade Behring Inc.). Resistance to imipenem and meropenem was confirmed by using Kirby-Bauer disk diffusion, according to the National Council for Clinical Laboratory Standards (NCCLS) guidelines. *A. baumannii* isolates were collected prospectively and stored at –70°C for further work-up.

**Analysis of Chromosomal DNA by Pulsed-Field Gel Electrophoresis (PFGE)**

Isolates of our patients, when available, were kept frozen at –70°C and genetically characterized with PFGE. DNA preparation and cleavage with 20 U of Apal endonuclease (New England Biolabs, Beverly, MA, USA) were performed as previously described (26). Electrophoresis was performed in a 1% agarose gel (BMA products) prepared and run in 0.5 x Tris-borate-EDTA buffer on a CHEF-DR III apparatus (Bio-Rad Laboratories, Hercules, CA, USA). The initial switch time was 5 s, the final switch time was 35 s, and the run time was 23 h at 6 V/cm. Gels were stained in ethidium bromide, destained in distilled water, and photographed by using a Bio-Rad GelDoc 2000 camera. DNA patterns were analyzed visually and by using Diversity software (Bio-Rad). PFGE DNA patterns were compared and interpreted according to the criteria of Tenover et al. (27). The obtained PFGE DNA patterns were used to cluster the clones of the *A. baumannii* clinical isolates that were included in the study.

**Definitions**

We defined *A. baumannii* as MDR when the organism was resistant to all studied agents (including piperacillin/tazobactam, cefepime, ceftazidime, aztreonam, ciprofloxacin, gentamicin, tobramycin), but we allowed susceptibility to amikacin, ampicillin-sulbactam, imipenem, meropenem, and minocycline. Infection was defined according to the Centers for Disease Control and Prevention guidelines and modified to include community-acquired infections and to exclude asymptomatic bacteriuria (28). Standard criteria were used to define underlying disorders. Disease was considered to be active if signs of disease were clinically apparent or if the patient received...
treatment for the disease. A patient was considered to be receiving immunosuppressive therapy if he had undergone chemotherapy within 3 weeks, if he had been treated with $\geq 20$ mg of prednisone daily for $\geq 2$ weeks before entering the study, or if he had recently received antirejection drugs or other immunosuppressive therapy.

Severity of illness due to comorbidities was defined according to the McCabe score (25). Functional capacity during the index hospitalization was divided into 3 categories: independent, needing help for activities of daily living, and bedridden. Renal failure was defined as a creatinine level $> 2$ mg/dL. Neurologic function was categorized according to 3 conditions: full consciousness, confusional state or dementia, and unconscious.

For each patient included in the study, we noted whether a susceptible \textit{A. baumannii} was isolated in any culture before isolation of the MDR strain. We noted the number of antimicrobial drugs that the patient received between the time of admission until inclusion in the study, and we recorded home antimicrobial drug therapy separately. Recent hospitalization was defined as hospital stay within 3 months of the index hospitalization. We noted any surgical procedure, mechanical ventilation, and invasive procedure that took place 1 month before the patient’s inclusion in the study.

**Statistical Analysis**

Statistics were run in Stata version 7 (Stata Corp., College Station, TX). All analyses were matched to correspond to the study design. All variables were examined by univariate analysis with the McNemar test and paired Student $t$ test. Variables with a $p$ value $< 0.2$ in the univariate analysis were included in the multivariate model. Risk factors were examined by using conditional logistic regression. A final model was built that included all the variables with a $p$ value $< 0.2$. Variables that were not retained in the model by this procedure were then tested for confounding by adding them 1 at a time to the model and examining their effects on the $\beta$ coefficients. Variables which caused substantial confounding (change in $\beta$ coefficient of $>10\%$) were included in the final model. After constructing the explanatory model, the effect of exposure to antimicrobial agents (i.e., antimicrobial treatment before inclusion in the study) was examined by adding them to the model.

In addition to examining statistical significance and confounding, the effect modification between variables was evaluated by testing appropriate interaction terms for statistical significance. Colinearity was examined by replacing variables with each other and examining the effect on the model. All statistical tests were 2-tailed. A $p$ value $\leq 0.05$ was considered significant.
isolation is required.” Epidemiologic nurses checked with
the ward to confirm that the patient was isolated. On cer-
tain floors, surveillance (nose, forearms, armpits, and
perirectal swabs) and environmental cultures (using swabs,
contact plates, and direct culturing of fluids) were per-
formed to try to identify a reservoir of organism. In this
study, case-patients and controls were matched by ward
and calendar time to focus on individual risk factors and
not on differences between wards and temporal changes.
A total of 51 unique patient MDR strains were available
for further study, and they were analyzed by using PFGE.
We identified 10 distinct clones of A. baumannii. Figure 3
shows 6 different PFGE-defined clones, each having from
1 to 4 subtypes showing a 1- to 2-band difference. Two of
the 10 different clones dominated: 22 case-patients had
clon e A and 10 case-patients had clone B, although no spe-
cific clone dominated in a specific ward but rather each
clon e was spread among several wards during the entire
study period (Table 1). We also found various antimicro-
bial drug susceptibility phenotypes (all belonging to our
definition of MDR) within each PFGE clone, but almost
city all cases of carbapenem resistance belonged to clone A.

Individual Risk Factors

The study patients’ characteristics are displayed in
Table 2. Case-patients were similar to their matched control
patients with respect to mean age (67.7 vs 64.4 years)
and sex distribution (men, n = 71 [60%] vs controls, n = 59
[50%]). The groups were also similar in habits of smoking
and alcohol consumption and in the occurrence of coexist-
ing conditions of lung disease, diabetes, kidney, liver dis-
 ease, malignancy, and posttransplantation condition. The
groups differed in the prevalence of ischemic heart dis-
ease: study case-patients 69% vs. controls 52% (OR 2.33,
p = 0.038), and to have a Foley catheter (OR 2.42, p = 0.005).
They were less likely to have had another bedside
surgical procedure before the isolation of A. baumannii
(OR 0.53, p = 0.035).

Several variables tended to be more associated with
case-patients, but the values did not reach statistical sig-
nificance: admission from another institute (OR 2.1, p =
0.06), unconsciousness (OR 0.706, p = 0.07), and previous
use of third-generation cephalosporin (OR 1.63, p = 0.093)
and of macrolides (OR 2.25, p = 0.056). A matched multi-
variate model, adjusted for the hospital length of stay, was
developed by using conditional logistic regression
(Table 3). The variables that were identified by this model
as being significant risk factors for MDR A. baumannii
were male sex (OR 3.8, p = 0.002), ischemic heart disease
(OR 3.3, p = 0.005), mechanical ventilation (OR 6.2, p <
0.001), and home antimicrobial drug use (OR 4.7, p =
0.018). Two agents used in the hospital were associated
with MDR A. baumannii: metronidazole was identified as
a risk factor (OR 2.3, p = 0.018), and the penicillin group
was identified as having a protective effect (OR = 0.38,
p = 0.029).

Discussion

We sought to understand the epidemiology of MDR A.
baumannii and to define the individual risk factors for
acquiring this infectious agent. Our findings illustrated its
complex epidemiology and delineated individual risk fac-
tors. The complex epidemiology may explain the difficul-
ties encountered in controlling the emergence of this
nosocomial pathogen.
Almost all cases of MDR A. baumannii in our study were hospital acquired: 88% were acquired in our institution during the index hospitalization, and 10% were imported into the hospital by patients with recent exposure to the healthcare system. The MDR A. baumannii strains isolated in our institution belonged to multiple PFGE clones: 50% of the isolates that were typed belonged to 2 dominant clones, and the other, nondominant clones caused few cases each.

Clones did not cluster in place (i.e., hospital location) or in time. Moreover, when an increase in incidence was observed in a certain ward, the increase was not associated with a single clone, and up to 4 different clones were present concomitantly in a ward. We also found antimicrobial susceptibility profile variation within clones and similarities between clones, which showed that susceptibility pattern was not a useful marker for clonality. Carbapenem resistance occurred in 75% of the isolates belonging to 1 of the 2 dominant clones (clone A) but was rare among other clones. This finding illustrates well the complexity of the epidemiology of this nosocomial pathogen. Even with molecular typing data, determining the modes of spread of this organism was difficult, partly because we did not have a complete collection of the isolates. Despite our expending extensive effort, we were unable to determine the source of these resistant strains. Although we believe that patient-to-patient transmission through contaminated hands of healthcare workers and fomites is the main route by which these MDR organisms spread, the combined epidemiologic and molecular data did not directly support this hypothesis. The lack of evidence for patient-to-patient spread in our study may be related to transferring patients between wards and the presence of a substantial number of undetected carriers (the “submerged iceberg phenomenon”) who spread the bacteria. Alternative explanations, such as repeated entry (import) of the same clone to the hospital ecosystem at various times and locations (e.g., from an disease-endemic institution or contaminated supply or food) must be considered as well.

The individual risk factors for isolation of MDR A. baumannii that were identified by the multivariate analysis were male sex, underlying comorbidity of ischemic heart disease, mechanical ventilation, and antimicrobial drug treatment. The finding of male sex and of ischemic heart disease being risk factors for carriage of and infection with resistant gram-negative bacilli had also been observed by our group, as well as by others for carriage of extended spectrum β-lactamase (ESBL) producing Enterobacteriaceae and Pseudomonas aeruginosa (29–31). We hypothesize that these associations may be related to the following factors: 1) patient-to-patient transmission within multipatient rooms (patients who are segregated by sex and need for intensive monitoring); 2) use of certain nonantimicrobial medication, such as calcium channel blockers, which may predispose for adherence or invasiveness by affecting the host or the pathogens (32,33); and 3) hormonal or other sex differences which may predispose a person for colonization and infection. These hypotheses are currently being studied in our facilities. The multivariate analysis did not identify admission from another institution as a significant risk factor. This probably relates to the small number (and proportion) of patients admitted from other institutions who were identified to be carriers of MDR A. baumannii. These few patients may, however, have played an important role to the entrance of new clones and the spread of the organisms within our institution. Moreover, case-patients that are not detected may still be important in the spread of these organisms. Overall, we believe that the identified risk factors represent both severity of the patient’s condition, use of invasive devices, and effect on the normal flora, all of which promote MDR A. baumannii colonization, growth, and invasiveness.

The administration of penicillin had a protective effect against isolation of MDR A. baumannii. This protective effect was significant after confounding by multivariate analysis was controlled for. Penicillins lack activity against these MDR strains, and the protective effect cannot relate to sulbactam, since a sulbactam combination is seldom used in our institution. To the best of our knowledge, such
an effect has not been observed previously. Specific penicillins may possibly cause specific changes in the microflora that oppose colonization and growth of *Acinetobacter* spp., but the validity of this observation awaits further research. As for many other resistant organisms, metronidazole was a significant risk factor for MDR *A. baumannii*, likely because of its effects on the competitive normal intestinal flora. The observation that carbapenem resistance was much more frequent in the dominant clone could suggest that this phenotype may have contributed to the evolutionary success of the clone.

A previous study clearly demonstrated that the epidemiology and risk factors may vary for different clones (17). This finding may lead to a dilution of effects and

### Table 2. Group comparison: patients' characterization and possible risk factors for *Acinetobacter baumannii* isolation

<table>
<thead>
<tr>
<th>Demographic parameters</th>
<th>Cases, n (%)</th>
<th>Controls, n (%)</th>
<th>OR</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average age, y (SD)</td>
<td>67.7 (16.42)</td>
<td>64.4 (19.15)</td>
<td>1.012</td>
<td>0.996–1.03</td>
<td>0.134</td>
</tr>
<tr>
<td>Female</td>
<td>47 (40)</td>
<td>59 (50)</td>
<td>1.48</td>
<td>0.89–2.45</td>
<td>0.13</td>
</tr>
<tr>
<td>Male</td>
<td>71 (60)</td>
<td>59 (50)</td>
<td>0.72</td>
<td>0.41–1.27</td>
<td>0.26</td>
</tr>
<tr>
<td>Smoking</td>
<td>35 (30)</td>
<td>43 (36)</td>
<td>1.5</td>
<td>0.42–5.31</td>
<td>0.53</td>
</tr>
<tr>
<td>Alcohol usage</td>
<td>7 (6)</td>
<td>5 (4)</td>
<td>2.12</td>
<td>0.96–4.76</td>
<td>0.065</td>
</tr>
<tr>
<td>Admission from home</td>
<td>23 (20)</td>
<td>12 (10)</td>
<td>0.923</td>
<td>0.53–1.6</td>
<td>0.777</td>
</tr>
</tbody>
</table>

### Concomitant diseases

| Ischemic heart disease | 82 (69) | 61 (52) | 2.33 | 1.27–4.27 | 0.006   |
| Lung disease           | 59 (50) | 50 (42) | 1.578 | 0.82–2.72 | 0.183   |
| Diabetes               | 39 (33) | 28 (24) | 1.578 | 0.88–2.8   | 0.119   |
| Liver disease          | 10 (8)  | 18 (15) | 0.555 | 0.25–1.2   | 0.136   |
| Kidney disease         | 35 (30) | 27 (23) | 1.388 | 0.76–2.54  | 0.288   |
| Posttransplantation     | 7 (6)   | 3 (3)   | 2.333 | 0.6–9.02  | 0.22    |
| Malignancy             | 35 (30) | 38 (32) | 0.923 | 0.53–1.6   | 0.777   |

### Clinical parameters

| Unconsciousness        | 40 (43) | 26 (22) | 0.706 | 0.48–1.02 | 0.069   |
| Bedridden              | 88 (75) | 79 (76) | 1.45  | 0.82–2.56 | 0.021   |
| In-house dialysis      | 11 (9)  | 4 (3)   | 2.5   | 0.78–7.97 | 0.121   |
| Mechanical ventilation | 70 (59) | 47 (40) | 2.916 | 1.51–5.61 | 0.001   |
| Admission in last 3 months | 56 (47) | 52 (44) | 1.148 | 0.68–1.92 | 0.6     |
| ICU stay               | 34 (22) | 35 (30) | 0.984 | 0.94–1.02 | 0.473   |
| Immunosuppression treatment | 29 (25) | 27 (32) | 1.095 | 0.9–1.97  | 0.763   |
| Major surgery          | 33 (28) | 33 (28) | 1     | 0.51–1.95 | 1       |

| Isolation of susceptible *Acinetobacter* before inclusion | 6 (5) | 6 (5) | 1 |

### Antimicrobial treatment

| Home antimicrobial treatment | 16 (41) | 6 (5) | 2.666 | 1.04–6.81 | 0.04 |
| In-house antimicrobial treatment | 104 (88) | 96 (81) | 1.727 | 0.82–3.63 | 0.149 |
| Average number of antimicrobial agents (SD) | 3.025 (2) | 2.97 (2) | 1.015 | 1 | 0.847 |
| Penicillin administration | 42 (63) | 54 (48) | 0.647 | 0.37–1.1 | 0.112 |
| Cephalosporin use (1st, 2nd generation) | 31 (26) | 34 (29) | 0.9 | 0.47–1.70 | 0.746 |
| 3rd generation cephalosporin use | 53 (54) | 42 (63) | 1.631 | 0.92–2.68 | 0.093 |
| 4th-generation cephalosporin use | 17 (41) | 17 (14) | 1 | 0.49–2.04 | 1 |
| Macrolides | 21 (18) | 11 (9) | 2.25 | 0.97–5.17 | 0.056 |
| Metronidazole | 48 (14) | 35 (30) | 1.933 | 1.03–3.6 | 0.038 |
| Gentamicin | 23 (19) | 27 (32) | 0.777 | 0.38–1.56 | 0.481 |
| Amikacin | 12 (10) | 19 (16) | 0.5 | 0.2–1.24 | 0.134 |
| Clindamycin | 7 (6) | 8 (7) | 0.875 | 0.32–2.41 | 0.796 |
| Vancomycin | 22 (19) | 22 (19) | 0.944 | 0.48–1.83 | 0.866 |
| Carbapenem | 10 (8.47) | 10 (8.47) | 0.875 | 0.32–2.41 | 0.796 |

| Invasive procedures | 79 (58) | 70 (59) | 0.958 | 0.54–1.7 | 0.884 |
| Arterial line | 35 (30) | 34 (29) | 0.933 | 0.45–1.93 | 0.85 |
| Foley catheter | 96 (81) | 76 (64) | 2.42 | 1.3–4.52 | 0.005 |

**Note:** OR, odds ratio; CI, confidence interval; SD, standard deviation; ICU, intensive care unit.

† Including semisynthetic penicillin and β-lactamase-containing products.

‡ Including tracheostomy, bedside débridement, chest tube insertion, and gastrointestinal endoscopy.

---

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 1, January 2005
even to opposing effects by some risk factors. In our study, we did not analyze clone-specific risk factors because we did not believe that we truly had an epidemic clone and because the number of patients affected by each clone was too small to allow a statistically significant comparison.

Temperospatial factors, although they undoubtedly have an important role in the spread of resistant organisms, were not within the scope of this study. We controlled for these factors by the study design, i.e., matching by hospital location, length of stay before inclusion in the study, and calendar time. Confounding may, however, have been introduced to our study by factors for which we did not control, such as residing in a multipatient room next to a patient with MDR A. baumannii.

We used risk set sampling (by matching for time at risk) but did not allow case-patients to be eligible to be controls before becoming cases. Since no clustering in time and place occurred, and controls were chosen from 35,000 admitted patients, this method of sampling should not have yielded biased results.

Despite the large number of cases that we identified, we were unable to understand the mode of spread and the reason for emergence of these organisms in our institution. This fact may be because only some of the isolates were available for typing or because of the complex mode of spread in our hospital. Further study will be required to more fully understand the intricate phenomenon of MDR A. baumannii spread.

Dr. Abbo is in clinical development at Biosense Webster (Israel). This work was part of his M.Sc. dissertation in internal medicine. His primary research interests include the clinical epidemiology of infectious diseases and cardiology.

References


Address for correspondence: Yehuda Carmeli, Division of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv 64239, Israel; fax: 972-3-6974966; email: ycarmeli@bidmc.harvard.edu

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is appreciated.